References
- Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Gallon D.A.G., Gralnick H.R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology 1982; 51: 189–199
- Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E., Bauters F., Fenaux P. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system/a report on 408 cases. Leukemia 1993; 7: 1315–23
- Raza A., Gezer S., Mundle S., Gao X.F., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus R., Khan Z., Chaney C., Showel J., Gregory S., Presley H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276
- Lepelley P., Campergue L., Preudhomme C., Grardel N., Cosson A., Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes?. British Journal of Haematology 1996; 95: 368–371
- Bogdanovic A.D., Jankovic G.M., Colovic M.D., Trpinac D.P., Bumbasierevic V.Z. Apoptosis in bone marrow of myelodysplastic syndrome patients. Blood 1996; 87: 3064
- Rajapaksa R., Ginzton N., Rott L.S., Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275–4287
- Oehm A., Berhmann I., Falk W., Pawlita M., Maier G., Klas C., Weber M.L., Richards S., Dhein J., Trauth B.C., Ponstingl H., Krammer P.H. Purification and molecular cloning of the APO1 cell surface antigen, a member of the TNF/NGF receptor superfamily. Journal of Biological Chemistry 1992; 267: 10709–715
- Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the Tumor Necrosis factor family. Cell. 1993; 75: 1169–1178
- Nagata S., Goldstein P. The Fas death factor. Science 1995; 267: 1449–1455
- Gersuk G.M., Lee J.W., Beckman C.A., Anderson J., Deeg H.J. Fas (CD95) receptor and Fas ligand expression in bone marrow cell from patients with myelodys-plastic syndrome. Blood 1996; 88: 1122–1126
- Lepelley P., Preudhomme C., Vanrumbeke M., Quesnel B., Cosson A., Fenaux P. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 1994; 8: 1342–1349
- Lepelley P., Soenen V., Preudhomme C., Merlat A., Cosson A., Fenaux P. Bcl-2 expression in myelodysplasia syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia 1995; 9: 725–730
- Maciejewski J., Selleri C., Anderson S., Young N.G. Fas antigen expression on CD34+ human marrow cells is induced by Interferon γ and Tumor Necrosis Factor α and potentiates cytokine-mediated hematopoietic suppression. in vitro. Blood 1995; 85: 3183–3190
- Verhoef G., De Schouwer P., Ceuppens J., Vandamme J., Goossens W., Boogaert M. Measurement of serum cytokine levels in Patients with myelodysplastic syndromes. Leukemia 1992; 2: 1268–1272
- Shetty V., Mundle S., Alvi S., Showel M., Broady-Robinson L.T., Dar S., Borok R., Showel J., Gregory S., Rifkin S., Gezer S., Parcharidou A., Venugopal P., Shah R., Hernandez B., Klein M., Alston D., Robin E., Dominquez C., Raza A. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia 1996; 20: 891–900